Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with DKD~* Mean eGFR ≥ 15 and \< 60 mL/min/1.73 m²~* Albumin/creatinine ratio (ACR) ≤ 3500 mg/g Cr~* Treatment with an angiotensin converting enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB) with no change in dosage or medication etc.~Exclusion Criteria:~* Diabetes mellitus that is neither type 1 nor type 2~* Decreased renal function mainly attributed to a non-diabetic cause~* History of renal transplantation or upcoming preemptive renal transplantation~* Confirmed mean systolic blood pressure \> 160 mmHg or a confirmed mean diastolic blood pressure \> 90 mmHg during the 8-week period before screening~* Hemoglobin A1c level \> 10.0% during screening~* Serum albumin level ≤ 3.0 g/dL during screening~* Cardiovascular disease specified in the study protocol~* History of cardiac failure~* BNP level \> 200 pg/mL during screening etc.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- RTA 402(Bardoxolone methyl) (Type: EXPERIMENTAL): Patients will receive multiple oral doses of bardoxolone methyl once daily. The starting dose of bardoxolone methyl will be 5 mg. The maximum dose will be 15 mg, and the dose will be increased by 5 mg.
- Placebo (Type: PLACEBO_COMPARATOR): Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.

Based on this trial design, predict the completion outcome and termination type (if applicable).